Semi-Synthetic Mithramycin SA Derivatives with Improved AntiCancer Activity

Natural Products As Sources of New Drugs over the 30 Years from 1981 to 2010

(2012) David J. Newman et al.   JOURNAL OF NATURAL PRODUCTS

Modification of olivomycin A at the side chain of the aglycon yields the derivative with perspective antitumor characteristics

(2011) Anna N. Tevyashova et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Combining Betulinic Acid and Mithramycin A Effectively Suppresses Pancreatic Cancer by Inhibiting Proliferation, Invasion, and Angiogenesis

(2011) Y. Gao et al.   CANCER RESEARCH

Nanoparticulate formulations of mithramycin analogs for enhanced cytotoxicity

(2011) Daniel Scott et al.   International Journal of Nanomedicine

Transcriptional Regulation of Pro-apoptotic Protein Kinase Cδ

(2011) Huajun Jin et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Mithramycin Is a Gene-Selective Sp1 Inhibitor That Identifies a Biological Intersection between Cancer and Neurodegeneration

(2011) S. F. Sleiman et al.   JOURNAL OF NEUROSCIENCE

Identification of an Inhibitor of the EWS-FLI1 Oncogenic Transcription Factor by High-Throughput Screening

(2011) Patrick J. Grohar et al.   JNCI-Journal of the National Cancer Institute

Therapeutic effects of the Sp1 inhibitor mithramycin A in glioblastoma

(2010) Janina Seznec et al.   JOURNAL OF NEURO-ONCOLOGY

Reaction of the antitumor antibiotic olivomycin I with aryl diazonium salts. Synthesis, cytotoxic and antiretroviral potency of 5-aryldiazenyl-6-O-deglycosyl derivatives of olivomycin I

(2009) Anna N. Tevyashova et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Erratum: Modification of the antibiotic olivomycin I at the 2′-keto group of the side chain. Novel derivatives, antitumor and topoisomerase I-poisoning activity

(2009) Anna N Tevyashova et al.   JOURNAL OF ANTIBIOTICS

Disulfide-cross-linked PEG-poly(amino acid)s copolymer micelles for glutathione-mediated intracellular drug delivery

(2008) Ahn Na Koo et al.   CHEMICAL COMMUNICATIONS